CALCNasdaq

CalciMedica, Inc.

Healthcare·Oncology·Phase 2·La Jolla, CA, United States
OncologyImmunologyCardiovascularInfectious DiseaseRespiratoryMusculoskeletalGastroenterology

CalciMedica, Inc. (CALC): 6 pipeline candidates · ~5 mo cash runway · 4 clinical trials. Updated within the last hour.

6.7/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.4

5.1 months

Financial Health9.6

D/E -8.80 · 4% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CalciMedica, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$13.7M

Cash

$8.2M

Quarterly Burn

$4.9M

Runway

5.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (6 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

28

Total value held

$618K

HolderSharesValue
vanguard capital management llc338,220$183K
jane street group, llc178,515$96K
renaissance technologies llc128,075$69K
180 wealth advisors, llc126,500$68K
geode capital management, llc123,382$67K
stonehage fleming financial services holdings ltd53,703$29K
vanguard fiduciary trust co45,829$25K
susquehanna international group, llp30,716$17K
citadel advisors llc18,200$10K
state street corp17,073$9K

Showing top 10 of 28 institutional holders of CalciMedica, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

4 clinical trials·1 FDA decision·CEO: Dr. A. Rachel Leheny Ph.D.

Frequently asked questions

How many drug candidates are in CalciMedica, Inc.'s pipeline?

CalciMedica, Inc. (CALC) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CalciMedica, Inc.'s lead drug candidate?

CalciMedica, Inc.'s most advanced tracked candidate is Auxora (Phase 2) for Pneumonia.

What is CalciMedica, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CalciMedica, Inc. has approximately 5.1 months of cash runway.

What is CalciMedica, Inc.'s market capitalization?

CalciMedica, Inc.'s market capitalization is approximately $13.7M.

Who is the CEO of CalciMedica, Inc.?

Dr. A. Rachel Leheny Ph.D. is the chief executive officer of CalciMedica, Inc. (CALC).

Get the full picture on CalciMedica, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.